We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma cell–directed therapy for rituximab-refractory PLA2R<sup>+</sup> membranous nephropathy.
- Authors
Salhi, Sofiane; Ribes, David; Fortenfant, Françoise; Faguer, Stanislas
- Abstract
This article discusses the use of plasma cell-directed therapy as a potential treatment for patients with rituximab-refractory PLA2R+ membranous nephropathy (MN). The study focuses on the use of a combination of bortezomib and dexamethasone (BD) in five patients with persistent anti-PLA2R autoimmunity despite multiple infusions of rituximab. The results showed that four out of five patients achieved an immunological response, and progressive renal response was observed in all patients. The study suggests that further research is needed to evaluate the efficacy of BD in a randomized comparative study.
- Subjects
KIDNEY diseases; RITUXIMAB; BORTEZOMIB
- Publication
Nephrology Dialysis Transplantation, 2023, Vol 38, Issue 12, p2851
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfad135